Results 101 to 110 of about 5,337 (191)

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease

Biomedicines
Alzheimer’s Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of amyloid beta1-40 and 1-42, and intracellular ...
Xiaoming Qi, Damir Nizamutdinov, Song Stephen Yi, Erxi Wu, Jason H. Huang   +4 more
doaj   +1 more source

Aducanumab-avwa

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform [PDF]

The US Food and Drug Administration’s controversial decision to grant accelerated approval to aducanumab (Aduhelm), a therapy for Alzheimer’s disease, has motivated multiple policy reforms.
Herder, Matthew
core   +2 more sources

Detection of extracellular amyloid beta aggregates by an Aducanumab-based synNotch receptor: an in vitro proof-of-concept study

Journal of Translational Medicine
Background Synthetic Notch (synNotch) receptors are a powerful gene regulation platform that activate transcription in response to membrane-bound ligands and extracellular matrix components, with emerging applications in cancer, autoimmunity, and ...
Nicholas J. Bergo, Suckwon Lee, Cynthia J. Siebrand, Zachary Mayeri, Julie K. Andersen, Chaska C. Walton   +5 more
doaj   +1 more source

A resurrection of aducanumab for Alzheimer's disease [PDF]

The Lancet Neurology, 2020
openaire   +2 more sources

Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease

Journal of Alzheimer's Disease Reports
Lecanemab has demonstrated amyloid reduction and slowed clinical decline in early Alzheimer's disease trials. Herein, we report retrospective case series results on lecanemab treatment in our clinic. Overall, 61 individuals were included.
Alyanna Ferrer, Justin Moon
doaj   +1 more source

Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature review

Journal of Education, Health and Sport
Introduction: Alzheimer's disease is an increasing problem in aging European societies. Almost 9 million Europeans already suffer from this disease.
Mateusz Michalak, Piotr Kucharczyk, Karolina Parzęcka, Michał Symulewicz, Olaf Domaradzki, Weronika Zań, Bartłomiej Kusy, Marta Stolińska, Kinga Szczepanik   +8 more
doaj   +1 more source

Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's disease (AD) will benefit more patients.
Hugo Geerts, Silke Bergeler, Mike Walker, Rachel H. Rose, Piet H. van derGraaf   +4 more
doaj   +1 more source

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

Alzheimer’s Research & Therapy
Background With the approval of disease-modifying treatments (DMTs) for early Alzheimer’s disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-β (Aβ) pathology. Current methods, including positron
Matthew D. Howe, Karysa J. Britton, Hannah E. Joyce, William Menard, Sheina Emrani, Zachary J. Kunicki, Melanie A. Faust, Brittany C. Dawson, Meghan C. Riddle, Edward D. Huey, Shorena Janelidze, Oskar Hansson, Stephen P. Salloway   +12 more
doaj   +1 more source

Aducanumab: The Controversial New Drug Licensed to Treat Alzheimer’s Disease [PDF]

Alzheimer’s Disease is a neurodegenerative condition that results in both cognitive and functional decline. It has a high prevalence in the developed world, accompanied by a large burden of disease.
Janes, Ava
core